Company Encyclopedia
View More
name
Prophase Labs
PRPH.US
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster.
4.514 T
PRPH.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking164/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-220.34%E
    • Profit Margin-825.00%E
    • Gross Margin-13.93%E
  • Growth ScoreB
    • Revenue YoY908.80%A
    • Net Profit YoY-50.25%D
    • Total Assets YoY-28.44%E
    • Net Assets YoY-82.00%E
  • Cash ScoreB
    • Cash Flow Margin-12.12%D
    • OCF YoY908.80%A
  • Operating ScoreE
    • Turnover0.06E
  • Debt ScoreE
    • Gearing Ratio89.56%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ProPhase Labs Inc. Held Special Shareholder Meeting

    ProPhase Labs Inc. held a Special Meeting of Stockholders on November 24, 2025, where shareholders approved proposals including digital asset acquisition, creation of digital treasury shares, issuance of digital tokens, and stock splits. Amendments to increase authorized common stock and potential meeting adjournment were also approved. This AI-generated brief is for informational purposes only and not financial advice.

    Reuters·
    US
    PRPH
    +3.47%
    Reuters·
    US
    PRPH
    +3.47%

    Prophase Labs- On Nov 21, Received Confirmation From Avtech Agreeing To Continue Its Forbearance Under Co's Existing Equipment Lease

    Nov 25 (Reuters) - Prophase Labs Inc:* PROPHASE LABS- ON NOV 21, RECEIVED CONFIRMATION FROM AVTECH AGREEING TO CONTINUE ITS FORBEARANCE UNDER CO'S EXISTING EQUIPMENT LEASE* PROPHASE LABS- UNDER AVTECH'S UPDATED PAYMENT SCHEDULE, CO TO MAKE WEEKLY PAYMENTS BEGINNING NOV 28, UNTIL OUTSTANDING PAST-DUE AMOUNTS ARE CURRENT* PROPHASE LABS INC - REMAINS IN COMMUNICATION WITH AVTECH REGARDING THESE PAYMENTS Source text: Further company coverage:

    Reuters·
    US
    PRPH
    +3.47%
    Reuters·
    US
    PRPH
    +3.47%

    Prophase Labs - Aware That Civil Action Pending In The United States District Court For The Eastern District Of New York Has Been Unsealed

    Prophase Labs Inc. is aware of a civil action unsealed in the U.S. District Court for the Eastern District of New York. The company denies any wrongdoing and asserts that its operations comply with standards. Prophase Labs expects no operational impact from the unsealed matter and plans to vigorously defend itself once formally served, according to an SEC filing.

    Reuters·
    US
    PRPH
    +3.47%
    Reuters·
    US
    PRPH
    +3.47%

    ProPhase Labs Faces Unsealed False Claims Act Lawsuit

    ProPhase Labs Inc. faces an unsealed False Claims Act lawsuit filed in 2023, revealed by the U.S. District Court for the Eastern District of New York. The company denies wrongdoing, asserting compliance with regulatory standards, and plans to defend itself vigorously. It does not expect the litigation to affect its operations. Previous disputes with the plaintiff were resolved in 2024. The news was generated by Public Technologies using AI and is based on ProPhase Labs' EDGAR filing.

    Reuters·
    US
    PRPH
    +3.47%
    Reuters·
    US
    PRPH
    +3.47%

    Prophase Labs | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 883 K

    LB filings·
    US
    PRPH
    +3.47%
    LB filings·
    US
    PRPH
    +3.47%
    © 2025 Longbridge｜Disclaimer